Medtronic’s Hugo Robot Achieves Primary Endpoints in Hernia Surgery Trial

Medtronic’s modular Hugo robotic-assisted surgery system has successfully met primary effectiveness and safety endpoints in a clinical trial. The study enrolled 193 patients undergoing inguinal or ventral hernia repair, achieving a 100% surgical success rate—exceeding the pre-specified 85% target. Surgical success was defined as completing the procedure without conversion to laparoscopy, open surgery, or an alternative robotic system.

Safety outcomes were positive, with no events among inguinal repair patients and a 2.1% event rate in ventral repair patients, well below the 30% performance threshold. Average hospital stays were 4.7 hours for inguinal and 6.7 hours for ventral procedures.

Hugo’s modular design allows flexible use of robotic arms and easy transfer between operating rooms. Medtronic has filed for urology authorization and plans to expand into hernia repairs, targeting a key segment of Intuitive Surgical’s market. The system’s versatility may provide advantages for procedures that do not require four robotic arms.

05-09-2025